Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience.
OBJECTIVE
To evaluate the survival of patients with glioblastoma multiforme (GBM) and analyse the prognostic factors influencing survival.


METHODS
Seventy-eight consecutive patients with GBM treated with radiotherapy (RT) and temozolomide (TMZ) (in 21 patients) between 1999 and 2006 were retrospectively analysed.


RESULTS
Sixty-seven (85.5%) patients had undergone gross total or subtotal resection before RT. The median overall survival was 9.8 months, and significantly influenced by age (p=0.02), Karnofsky performance status (p=0.001), RT (p<0.0001), gender (p=0.02), concomitant TMZ (p=0.003), RT waiting time (p=0.014), and treatment time (p=0.01) in univariate analysis. In multivariate analysis, older age (p=0.03), male gender (p=0.01), absence of concomitant TMZ (p=0.008), RT dose below 60 Gy (p=0.03), RT waiting time more than 20 days (p=0.01), and treatment time more than 76 days (p=0.0072) were poor prognosticators.


CONCLUSIONS
This study emphasizes the importance of female gender, dose and duration of RT, and RT waiting time in patients with glioblastoma multiforme.
Caloglu
M
M
Department of Radiation Oncology, Trakya University Hospital, Edirne, Turkey. caloglumurat@hotmail.com
Yurut-Caloglu
V
V
Karagol
H
H
Bayir-Angin
G
G
Turan
F N
FN
Uzal
C
C
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012737:Sex Factors; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome; D055815:Young Adult
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide